Definium Therapeutics (NASDAQ:DFTX) Shares Down 8.1% – Time to Sell?

Posted by on Nov 4th, 2026

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX – Get Free Report) fell 8.1% during mid-day trading on Monday. The stock traded as low as $33.37 and last traded at $33.37. Approximately 506,365 shares changed hands during trading, a decline of 77% from the average daily volume of 2,225,133 shares. The stock had previously closed at $36.33.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday, October 15th. Needham & Company LLC reiterated a “buy” rating and set a $66.00 price objective on shares of Definium Therapeutics in a report on Monday, September 14th. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Definium Therapeutics in a research report on Monday, September 14th. Oppenheimer reaffirmed an “outperform” rating and set a $75.00 target price on shares of Definium Therapeutics in a research report on Monday, September 14th. Finally, JPMorgan Chase & Co. assumed coverage on Definium Therapeutics in a research note on Friday, October 9th. They issued an “overweight” rating and a $84.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Definium Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $66.00.

Get Our Latest Analysis on DFTX

Definium Therapeutics Stock Performance

The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The business’s 50-day simple moving average is $37.32 and its two-hundred day simple moving average is $29.69. The firm has a market cap of $4.39 billion, a price-to-earnings ratio of -9.53 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, sell-side analysts expect that Definium Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.

Insider Activity at Definium Therapeutics

In other Definium Therapeutics news, CEO Robert Barrow sold 31,550 shares of the stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $1,153,783.50. Following the completion of the transaction, the chief executive officer owned 2,213,090 shares of the company’s stock, valued at $80,932,701.30. This represents a 1.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Sullivan sold 14,051 shares of the stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $513,845.07. Following the completion of the sale, the insider owned 494,228 shares of the company’s stock, valued at $18,073,917.96. This trade represents a 2.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 71,098 shares of company stock valued at $2,626,115. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of DFTX. Wellington Management Group LLP purchased a new position in shares of Definium Therapeutics in the 2nd quarter valued at about $138,755,000. Bank of New York Mellon Corp lifted its position in Definium Therapeutics by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock worth $36,563,000 after acquiring an additional 24,349 shares during the period. Alps Advisors Inc. boosted its holdings in shares of Definium Therapeutics by 61.3% in the third quarter. Alps Advisors Inc. now owns 178,006 shares of the company’s stock valued at $6,775,000 after acquiring an additional 67,618 shares in the last quarter. Moody Aldrich Partners LLC boosted its stake in shares of Definium Therapeutics by 191.8% in the third quarter. Moody Aldrich Partners LLC now owns 148,870 shares of the company’s stock valued at $5,666,000 after buying an additional 97,845 shares in the last quarter. Finally, Seven Fleet Capital Management LP purchased a new stake in Definium Therapeutics during the second quarter worth about $6,992,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

(Get Free Report)

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

Featured Stories

Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.